{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:42Z","timestamp":1788454842450,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T00:00:00Z","timestamp":1704585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204527"],"award-info":[{"award-number":["82204527"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2208085QH279"],"award-info":[{"award-number":["2208085QH279"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejps.2024.106697","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:48:36Z","timestamp":1704714516000},"page":"106697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy"],"prefix":"10.1016","volume":"194","author":[{"given":"Liang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus T.","family":"Olkkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Dallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-7601","authenticated-orcid":false,"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106697_bib0001","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clpt.2005.09.001","article-title":"Effect of low-dose ritonavir (100mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers","volume":"78","author":"Aarnoutse","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920927276","article-title":"Chronic pain in HIV","volume":"16","author":"Addis","year":"2020","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejps.2024.106697_bib0003","first-page":"12","article-title":"Challenges in the management of chronic pain in HIV\/AIDS","volume":"26","author":"Almeida","year":"2014","journal-title":"HIV Clin."},{"key":"10.1016\/j.ejps.2024.106697_bib0004","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106697_bib0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13318-022-00765-w","article-title":"A mechanistic absorption and disposition model of ritonavir to predict exposure and drug-drug interaction potential of CYP3A4\/5 and CYP2D6 substrates","volume":"47","author":"Arora","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106697_bib0006","doi-asserted-by":"crossref","first-page":"10345","DOI":"10.1021\/acs.jmedchem.7b01922","article-title":"Why are the majority of active compounds in the CNS domain natural products? A critical analysis","volume":"61","author":"Bharate","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2024.106697_bib0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2024.106697_bib0008","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fphar.2018.01210","article-title":"Postmortem toxicology of new synthetic opioids","volume":"9","author":"Concheiro","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106697_bib0009","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","article-title":"Atazanavir: a review of its use in the management of HIV-1 infection","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2024.106697_bib0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clpt.2005.11.009","article-title":"Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir","volume":"79","author":"Culm-Merdek","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0011","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2024.106697_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2011.00004","article-title":"A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks","volume":"2","author":"Eissing","year":"2011","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejps.2024.106697_bib0013","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0014","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106697_bib0015","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.xphs.2020.04.023","article-title":"Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling-case example ritonavir","volume":"109","author":"Fiolka","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106697_bib0016","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"Foisy","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejps.2024.106697_bib0017","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/psp4.12636","article-title":"A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions","volume":"10","author":"Frechen","year":"2021","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106697_bib0018","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/pme.12417","article-title":"Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness","volume":"15","author":"Fudin","year":"2014","journal-title":"Pain Med."},{"key":"10.1016\/j.ejps.2024.106697_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020270","article-title":"Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach","volume":"13","author":"Fuhr","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106697_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/phar.1682","article-title":"Lack of an effect of ritonavir alone and lopinavir-ritonavir on the pharmacokinetics of fenofibric acid in healthy volunteers","volume":"36","author":"Gordon","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2024.106697_bib0021","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1365-2125.2009.03545.x","article-title":"Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase","volume":"68","author":"Greenblatt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106697_bib0022","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.41.5.898","article-title":"Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects","volume":"41","author":"Hsu","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106697_bib0023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2125.2001.01393.x","article-title":"Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers","volume":"51","author":"Khaliq","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106697_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020284","article-title":"In silico simulation of the systemic drug exposure following the topical application of opioid analgesics in patients with cutaneous lesions","volume":"13","author":"Khotimchenko","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106697_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated clinical pharmacokinetics and pharmacodynamics of oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106697_bib0026","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106697_bib0027","first-page":"552","article-title":"Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4\/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir","volume":"26","author":"Koudriakova","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106697_bib0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/17425255.2015.996546","article-title":"Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems","volume":"11","author":"Kumar","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2024.106697_bib0029","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106697_bib0031","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpainsymman.2009.05.013","article-title":"Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics","volume":"38","author":"Lee","year":"2009","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.ejps.2024.106697_bib0032","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","article-title":"Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective","volume":"39","author":"Lin","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106697_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2024.106697_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2008.168","article-title":"Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure","volume":"85","author":"Mathias","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187231210790980453","article-title":"Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes","volume":"4","author":"Mugundu","year":"2010","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.ejps.2024.106697_bib0036","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-010-0879-1","article-title":"Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir\/ritonavir","volume":"66","author":"Nieminen","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106697_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/biom12070944","article-title":"Saquinavir: from HIV to COVID-19 and cancer treatment","volume":"12","author":"Pereira","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejps.2024.106697_bib0038","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106697_bib0039","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106697_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpba.2016.09.024","article-title":"Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases","volume":"144","author":"Romand","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2024.106697_bib0041","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1124\/jpet.116.235192","article-title":"Intranasal opioid administration in rhesus monkeys: PET imaging and antinociception","volume":"359","author":"Saccone","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106697_bib0042","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/17425255.2014.856882","article-title":"Exploring concepts of in vitro time-dependent CYP inhibition assays","volume":"10","author":"Stresser","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2024.106697_bib0043","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2010.06.003","article-title":"Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs","volume":"76","author":"Willmann","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2024.106697_bib0044","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/01.aids.0000183626.74299.77","article-title":"MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells","volume":"19","author":"Woodahl","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ejps.2024.106697_bib0045","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1021\/acs.molpharmaceut.7b00552","article-title":"In vitro characterization of ritonavir drug products and correlation to human in vivo performance","volume":"14","author":"Xu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2024.106697_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11095-019-2708-2","article-title":"Physiologically based pharmacokinetic modeling of oxycodone in children to support pediatric dosing optimization","volume":"36","author":"Zheng","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106697_bib0047","article-title":"Physiologically based pharmacokinetic modeling in pregnant women suggests minor decrease in maternal exposure to olanzapine","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:08:45Z","timestamp":1760530125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S0928098724000083"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106697","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106697"}}